Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vimpat lacosamide: Phase III data

In a double-blind Phase III trial in 551 patients, 400 mg/day of Vimpat met the primary endpoint of a

Read the full 192 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE